AI Engines For more Details: Perplexity Kagi Labs You
Erectile Dysfunction Treatment: Vardenafil belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors. It works by increasing blood flow to the penis during sexual stimulation, which helps men with ED achieve and maintain an erection.
Improved Sexual Function: Vardenafil can help improve erectile function in men with ED, allowing them to engage in satisfactory sexual activity. It is effective for many men, including those with underlying medical conditions such as diabetes or prostate surgery-related ED.
Rapid Onset of Action: Vardenafil typically begins to work within 30 to 60 minutes after ingestion. This relatively quick onset of action allows for spontaneity in sexual activity, as the medication does not need to be taken hours in advance.
Duration of Action: The effects of vardenafil can last for up to four to six hours, depending on the individual's response and the dose taken. This prolonged duration of action provides a window of opportunity for sexual activity.
Different Formulations: Vardenafil is available in various formulations, including tablets (Levitra), orally disintegrating tablets (Levitra ODT), and orally disintegrating films (Staxyn). These different formulations offer convenience and flexibility in dosing.
Safety Profile: Vardenafil is generally well-tolerated, but like any medication, it can cause side effects in some individuals. Common side effects may include headache, flushing, nasal congestion, indigestion, and dizziness. These side effects are usually mild to moderate and transient in nature.
Drug Interactions: Vardenafil can interact with certain medications, particularly nitrates and alpha-blockers, which are used to treat cardiovascular conditions such as angina and high blood pressure. Concomitant use of vardenafil with these drugs can lead to a sudden drop in blood pressure, posing a risk of serious complications.
Contraindications: Vardenafil is contraindicated in individuals who are taking nitrates or nitric oxide donors, as well as those with a history of cardiovascular disease, severe liver or kidney impairment, or certain eye conditions such as retinitis pigmentosa.
Priapism: In rare cases, vardenafil and other PDE5 inhibitors have been associated with priapism, a prolonged and painful erection lasting more than four hours. Priapism requires immediate medical attention to prevent tissue damage and permanent erectile dysfunction.
Vision Changes: Some users of vardenafil have reported visual disturbances, such as changes in color vision or blurred vision. These side effects are uncommon but should be reported to a healthcare provider if they occur.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Anaerobutyricum hallii | Reduces |
| species | Blautia wexlerae | Reduces |
| species | Christensenella minuta | Reduces |
| species | Faecalibacterium prausnitzii | Reduces |
| species | Lactococcus cremoris | Reduces |
| species | Lactococcus lactis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Anaerobutyricum | genus | Decreases |
| 0 | 1 | Pseudobutyrivibrio | genus | Decreases |
| 0 | 1 | Wansuia | genus | Decreases |
| 0 | 1 | Wujia | genus | Decreases |
| 0 | 1 | Butyrivibrio | genus | Decreases |
| 0 | 1 | Subdoligranulum | genus | Decreases |
| 0 | 1 | Anaerostipes | genus | Decreases |
| 0 | 1 | Komagataeibacter | genus | Decreases |
| 0 | 1 | Intestinibaculum | genus | Decreases |
| 0 | 1 | Simiaoa | genus | Decreases |
| 0 | 1 | Massilistercora | genus | Decreases |
| 0 | 1 | Faecalitalea | genus | Decreases |
| 0 | 1 | Ligilactobacillus | genus | Decreases |
| 0 | 1 | Catenibacterium | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Treponema | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lachnoclostridium | genus | Decreases |
| 0 | 1 | Christensenella | genus | Decreases |
| 0 | 1 | Faecalibacillus | genus | Decreases |
| 0 | 1 | Lachnoanaerobaculum | genus | Decreases |
| 0 | 1 | Qiania | genus | Decreases |
| 0 | 1 | Allocoprobacillus | genus | Decreases |
| 0 | 1 | Marvinbryantia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Eubacterium ventriosum | species | Decreases |
| 0 | 1 | Wansuia hejianensis | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 0 | 1 | Ligilactobacillus ruminis | species | Decreases |
| 0 | 1 | Komagataeibacter oboediens | species | Decreases |
| 0 | 1 | Roseburia rectibacter | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 0 | 1 | Subdoligranulum variabile | species | Decreases |
| 0 | 1 | Butyrivibrio crossotus | species | Decreases |
| 0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
| 0 | 1 | Faecalibacillus intestinalis | species | Decreases |
| 0 | 1 | Clostridium sp. SY8519 | species | Decreases |
| 0 | 1 | Intestinibaculum porci | species | Decreases |
| 0 | 1 | [Ruminococcus] lactaris | species | Decreases |
| 0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
| 0 | 1 | Clostridium sp. M62/1 | species | Decreases |
| 0 | 1 | Anaerostipes hadrus | species | Decreases |
| 0 | 1 | Coprococcus eutactus | species | Decreases |
| 0 | 1 | Blautia liquoris | species | Decreases |
| 0 | 1 | Massilistercora timonensis | species | Decreases |
| 0 | 1 | Faecalibacterium duncaniae | species | Decreases |
| 0 | 1 | Adlercreutzia equolifaciens | species | Decreases |
| 0 | 1 | Christensenella minuta | species | Decreases |
| 0 | 1 | Bacillus paralicheniformis | species | Decreases |
| 0 | 1 | Wujia chipingensis | species | Decreases |
| 0 | 1 | Coprococcus sp. ART55/1 | species | Decreases |
| 0 | 1 | Faecalitalea cylindroides | species | Decreases |
| 0 | 1 | Lachnoanaerobaculum gingivalis | species | Decreases |
| 0 | 1 | Catenibacterium mitsuokai | species | Decreases |
| 0 | 1 | Qiania dongpingensis | species | Decreases |
| 0 | 1 | Novisyntrophococcus fermenticellae | species | Decreases |
| 0 | 1 | [Clostridium] hylemonae | species | Decreases |
| 0 | 1 | Roseburia hominis | species | Decreases |
| 0 | 1 | Vescimonas fastidiosa | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I2-3-92 | species | Decreases |
| 0 | 1 | Mageeibacillus indolicus | species | Decreases |
| 0 | 1 | Blautia wexlerae | species | Decreases |
| 0 | 1 | Ruminococcus bicirculans (ex Wegman et al. 2014) | species | Decreases |
| 0 | 1 | Faecalibacterium sp. IP-3-29 | species | Decreases |
| 0 | 1 | Ruminococcus gauvreauii | species | Decreases |
| 0 | 1 | Fannyhessea vaginae | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I4-1-79 | species | Decreases |
| 0 | 1 | Maliibacterium massiliense | species | Decreases |
| 0 | 1 | Catenibacterium sp. co_0103 | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 0 | 1 | Vescimonas coprocola | species | Decreases |
| 0 | 1 | Faecalibacterium sp. IP-1-18 | species | Decreases |
| 0 | 1 | Monoglobus pectinilyticus | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I4-3-84 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. HTF-F | species | Decreases |
| 0 | 1 | Longicatena caecimuris | species | Decreases |
| 0 | 1 | Parvimonas micra | species | Decreases |
| 0 | 1 | Treponema peruense | species | Decreases |
| 0 | 1 | Mogibacterium diversum | species | Decreases |
| 0 | 1 | Ruminococcus champanellensis | species | Decreases |
| 0 | 1 | Lactococcus cremoris | species | Decreases |
| 0 | 1 | Actinomyces oris | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I3-3-33 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I3-3-89 | species | Decreases |
| 0 | 1 | Streptococcus suis | species | Decreases |
| 0 | 1 | Clostridium cadaveris | species | Decreases |
| 0 | 1 | Lachnoclostridium phocaeense | species | Decreases |
| 0 | 1 | Actinomyces naeslundii | species | Decreases |
| 0 | 1 | Eubacterium sp. c-25 | species | Decreases |
| 0 | 1 | Marvinbryantia formatexigens | species | Decreases |
| 0 | 1 | Eubacterium limosum | species | Decreases |
| 0 | 1 | Simiaoa sunii | species | Decreases |
| 0 | 1 | Faecalibaculum rodentium | species | Decreases |
| 0 | 1 | Enterococcus cecorum | species | Decreases |
| 0 | 1 | Treponema denticola | species | Decreases |
| 0 | 1 | Ruminococcus albus | species | Decreases |
| 0 | 1 | Flintibacter sp. KGMB00164 | species | Decreases |
| 0 | 1 | Corynebacterium durum | species | Decreases |
| 0 | 1 | Olsenella sp. oral taxon 807 | species | Decreases |
| 0 | 1 | Romboutsia ilealis | species | Decreases |
| 0 | 1 | Oscillibacter hominis | species | Decreases |
| 0 | 1 | [Eubacterium] hominis | species | Decreases |
| 0 | 1 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Solibaculum mannosilyticum | species | Decreases |
| 0 | 1 | Adlercreutzia hattorii | species | Decreases |
| 0 | 1 | Faecalibacterium prausnitzii | species | Decreases |
| 0 | 1 | Gordonibacter urolithinfaciens | species | Decreases |
| 0 | 1 | Eubacterium callanderi | species | Decreases |
| 0 | 1 | Emergencia timonensis | species | Decreases |
| 0 | 1 | Ruthenibacterium lactatiformans | species | Decreases |
| 0 | 1 | Ruminococcus bovis | species | Decreases |
| 0 | 1 | Pusillibacter faecalis | species | Decreases |
| 0 | 1 | Lawsonibacter asaccharolyticus | species | Decreases |
| 0 | 1 | Intestinimonas butyriciproducens | species | Decreases |
| 0 | 1 | Phascolarctobacterium succinatutens | species | Decreases |
| 0 | 1 | Blautia pseudococcoides | species | Decreases |
| 0 | 1 | Phoenicibacter congonensis | species | Decreases |
| 0 | 1 | Anaerotruncus colihominis | species | Decreases |
| 0 | 1 | Phascolarctobacterium sp. Marseille-Q4147 | species | Decreases |
| 0 | 1 | Amedibacterium intestinale | species | Decreases |
| 0 | 1 | Butyricicoccus sp. GAM44 | species | Decreases |
| 0 | 1 | Turicibacter bilis | species | Decreases |
| 0 | 1 | Arabiibacter massiliensis | species | Decreases |
| 0 | 1 | Eubacterium maltosivorans | species | Decreases |
| 0 | 1 | Lactococcus lactis | species | Decreases |
| 0 | 1 | Acutalibacter muris | species | Decreases |
| 0 | 1 | Alistipes communis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 1.2 | 1 | 0.2 |
| Age-Related Macular Degeneration and Glaucoma | 0.9 | 0.1 | 8 |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.3 | 4 |
| Allergies | 2.6 | 0.8 | 2.25 |
| Allergy to milk products | 1.3 | 0.8 | 0.63 |
| Alopecia (Hair Loss) | 1 | 0.1 | 9 |
| Alzheimer's disease | 2.9 | 5.6 | -0.93 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.1 | 16 |
| Ankylosing spondylitis | 1.5 | 0.7 | 1.14 |
| Anorexia Nervosa | 0.7 | 3 | -3.29 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 2.4 | 1.2 | 1 |
| Atherosclerosis | 1.5 | 1.1 | 0.36 |
| Atrial fibrillation | 3.2 | 1.3 | 1.46 |
| Autism | 4.2 | 4.5 | -0.07 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.4 | -0.4 | |
| Bipolar Disorder | 0.9 | 1.1 | -0.22 |
| Brain Trauma | 0.1 | 1.2 | -11 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.1 | -0.1 | |
| Carcinoma | 1.8 | 1.7 | 0.06 |
| Celiac Disease | 1.9 | 1.7 | 0.12 |
| Cerebral Palsy | 0.4 | 1.7 | -3.25 |
| Chronic Fatigue Syndrome | 1.4 | 4.5 | -2.21 |
| Chronic Kidney Disease | 1.7 | 3 | -0.76 |
| Chronic Lyme | 0.9 | -0.9 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 1.3 | -1.6 |
| Chronic Urticaria (Hives) | 0.8 | -0.8 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | 1.7 | -7.5 |
| Cognitive Function | 1 | 0.7 | 0.43 |
| Colorectal Cancer | 3.1 | 1.7 | 0.82 |
| Constipation | 0.7 | 1 | -0.43 |
| Coronary artery disease | 1.1 | 3.7 | -2.36 |
| COVID-19 | 2.6 | 6.7 | -1.58 |
| Crohn's Disease | 3.8 | 4.8 | -0.26 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.4 | -1.4 | |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1.3 | 1.6 | -0.23 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 4 | 5.6 | -0.4 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.1 | 0.6 | -5 |
| Endometriosis | 1.8 | 1.2 | 0.5 |
| Epilepsy | 2.1 | 1.2 | 0.75 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 1.6 | 1.2 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 2.7 | 3.7 | -0.37 |
| gallstone disease (gsd) | 1.6 | 0.5 | 2.2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1.3 | -0.63 |
| Generalized anxiety disorder | 1.6 | 0.9 | 0.78 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.6 | 0.5 | 0.2 |
| Graves' disease | 0.7 | 2.1 | -2 |
| Gulf War Syndrome | 1 | 0.6 | 0.67 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 3.4 | 1.5 | 1.27 |
| Heart Failure | 1.7 | 2.3 | -0.35 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.1 | 4 |
| hyperglycemia | 1.2 | -1.2 | |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 2.5 | 3.3 | -0.32 |
| Hypothyroidism | 0.1 | 1.4 | -13 |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 0.8 | 0.9 | -0.13 |
| Inflammatory Bowel Disease | 1.8 | 6.2 | -2.44 |
| Insomnia | 1.9 | 2.1 | -0.11 |
| Intelligence | 0.9 | 0.4 | 1.25 |
| Intracranial aneurysms | 1.2 | 0.5 | 1.4 |
| Irritable Bowel Syndrome | 3.4 | 2.1 | 0.62 |
| ischemic stroke | 1.2 | 1.5 | -0.25 |
| Juvenile idiopathic arthritis | 0.1 | -0.1 | |
| Liver Cirrhosis | 3.9 | 2.1 | 0.86 |
| Long COVID | 3 | 4.9 | -0.63 |
| Low bone mineral density | 1.6 | -1.6 | |
| Lung Cancer | 1.1 | -1.1 | |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 2.8 | -2.8 | |
| ME/CFS without IBS | 0.2 | 1.4 | -6 |
| Menopause | 0.2 | 0.6 | -2 |
| Metabolic Syndrome | 3.8 | 3.9 | -0.03 |
| Mood Disorders | 3.9 | 4.1 | -0.05 |
| multiple chemical sensitivity [MCS] | 0.6 | -0.6 | |
| Multiple Sclerosis | 1 | 4.6 | -3.6 |
| Multiple system atrophy (MSA) | 0.1 | 0.6 | -5 |
| myasthenia gravis | 0.1 | 0.6 | -5 |
| neuropathic pain | 1.4 | -1.4 | |
| Neuropathy (all types) | 0.6 | 0.7 | -0.17 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 3.9 | -0.86 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.4 | 1.25 |
| Obesity | 4.7 | 4.3 | 0.09 |
| obsessive-compulsive disorder | 2.4 | 2.8 | -0.17 |
| Osteoarthritis | 1.3 | 1 | 0.3 |
| Osteoporosis | 1.1 | 1.4 | -0.27 |
| Parkinson's Disease | 4.3 | 5.9 | -0.37 |
| Polycystic ovary syndrome | 3.8 | 1.6 | 1.37 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.5 | -4 |
| Premenstrual dysphoric disorder | 0.5 | 0.1 | 4 |
| primary biliary cholangitis | 0.2 | 0.2 | |
| Primary sclerosing cholangitis | 0.5 | 2.7 | -4.4 |
| Psoriasis | 1.6 | 2.5 | -0.56 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.2 | 3.7 | -0.16 |
| Rosacea | 0.7 | 0.6 | 0.17 |
| Schizophrenia | 2.1 | 2.5 | -0.19 |
| scoliosis | 0.8 | 0.2 | 3 |
| sensorineural hearing loss | 0.3 | 0.3 | |
| Sjögren syndrome | 0.9 | 1.9 | -1.11 |
| Sleep Apnea | 1.4 | 2.1 | -0.5 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 1.4 | 1.6 | -0.14 |
| Systemic Lupus Erythematosus | 2.2 | 1.5 | 0.47 |
| Tic Disorder | 0.1 | 0.7 | -6 |
| Tourette syndrome | 0.2 | 0.4 | -1 |
| Type 1 Diabetes | 2.4 | 1.5 | 0.6 |
| Type 2 Diabetes | 4.5 | 3.5 | 0.29 |
| Ulcerative colitis | 2.5 | 3.2 | -0.28 |
| Unhealthy Ageing | 2.3 | 1.9 | 0.21 |
| Vitiligo | 1.5 | 0.8 | 0.88 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
